Desensitization Using Bortezomib and High-dose Immunoglobulin Increases Rate of Deceased Donor Kidney Transplantation

Combination therapy of intravenous immunoglobulin (IVIG) and rituximab showed a good transplant rate in highly sensitized wait-listed patients for deceased donor kidney transplantation (DDKT), but carried the risk of antibody-mediated rejection. The authors investigated the impact of a new combinati...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeong, Jong Cheol, Jambaldorj, Enkthuya, Kwon, Hyuk Yong, Kim, Myung-Gyu, Im, Hye Jin, Jeon, Hee Jung, In, Ji Won, Han, Miyeun, Koo, Tai Yeon, Chung, Junho, Song, Eun Young, Ahn, Curie, Yang, Jaeseok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
4500
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4748896/
https://www.ncbi.nlm.nih.gov/pubmed/26844479
http://dx.doi.org/10.1097/MD.0000000000002635

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4748896/
https://www.ncbi.nlm.nih.gov/pubmed/26844479
http://dx.doi.org/10.1097/MD.0000000000002635

Ejemplares similares